Meeting
2023 ASCO Genitourinary Cancers Symposium
A phase II trial of combination of PD-1 immune checkpoint inhibition with all-lesion stereotactic radiation (SBRT) in oligometastatic renal cell carcinoma (omRCC).
Authors
Jing Liu
Shandong Cancer Hospital Affiliated to Shandong First Medical University, Jinan, China
Jing Liu , Benkui Zou , Chao Zhang , Kunli Zhu , Rui Feng , Lei Xu , Xue Dou , Pengyue Shi , Yun Zhang , Jinbo Yue
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
ChiECRCT20210046
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 677)
DOI
10.1200/JCO.2023.41.6_suppl.677
Abstract #
677
Poster Bd #
H9
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).
First Author: Cristina Masini
Poster
2023 ASCO Annual Meeting
Risk of immune-related adverse events (irAE) with immune checkpoint inhibitors (ICI) in patients (pts) with family history (FH) of autoimmune disease (AID).
First Author: Piyush Grover
Poster
2023 ASCO Annual Meeting
Phase II trial of XmAb20717 (vudalimab) in patients with advanced biliary tract cancers.
First Author: William Joseph Chapin
Poster
2023 ASCO Genitourinary Cancers Symposium
NRG-GU011: A phase II double-blinded, placebo-controlled trial of prostate oligometastatic radiotherapy with or without androgen deprivation therapy in oligometastatic prostate cancer (NRG PROMETHEAN).
First Author: Bridget F. Koontz